Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury-Reference-Cited by-同舟云学术

Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury

Published:2023-05-01 Issue:5 Volume:324 Page:F472-F482
ISSN:1931-857X
Container-title:American Journal of Physiology-Renal Physiology
language:en
Short-container-title:American Journal of Physiology-Renal Physiology

Author:

Hernandez Antonio¹^ORCID,Patil Naeem K.¹,Brewer Maya²^ORCID,Delgado Rachel²,Himmel Lauren³,Lopez Lauren N.²,Bohannon Julia K.¹³,Owen Allison M.¹^ORCID,Sherwood Edward R.¹³^ORCID,de Caestecker Mark P.²

Affiliation:

1. Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, United States

2. Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States

3. Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee, United States

Abstract

Pretreatment with 3-deacyl 6-acyl phosphorylated hexaacyl disaccharide; a novel synthetic Toll-like receptor 4 agonist, preserves kidney function during ischemia-reperfusion injury-induced acute kidney injury.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases

HHS | NIH | National Institute of General Medical Sciences

U.S. Department of Defense

Publisher

American Physiological Society

Subject

Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajprenal.00248.2022

Reference40 articles.